Theophylline exerts its bronchodilatory effect primarily through which mechanism?

Explanation

## Theophylline Mechanism of Action **Key Point:** Theophylline is a methylxanthine that inhibits phosphodiesterase (PDE), preventing the breakdown of cAMP and cGMP, thereby increasing intracellular cyclic nucleotide levels and causing bronchial smooth muscle relaxation. ### Molecular Mechanism 1. **Phosphodiesterase Inhibition:** Theophylline non-selectively inhibits PDE enzymes, particularly PDE3 and PDE4 in airway smooth muscle. 2. **cAMP Accumulation:** Reduced PDE activity → increased intracellular cAMP → activation of protein kinase A (PKA). 3. **Smooth Muscle Relaxation:** PKA phosphorylates myosin light-chain kinase (MLCK), reducing calcium sensitivity and causing bronchial smooth muscle relaxation. ### Chemical Structure Theophylline is a dimethylxanthine derivative (1,3-dimethylxanthine), structurally related to caffeine. **High-Yield:** The PDE inhibition mechanism is the PRIMARY bronchodilatory action; additional effects (immunomodulation, respiratory stimulation) are secondary. ### Additional Pharmacological Effects - **Respiratory stimulation:** Direct stimulation of respiratory centers (useful in apnea of prematurity) - **Immunomodulation:** Reduces inflammatory cell activation and cytokine release - **Cardiac effects:** Positive inotropic and chronotropic effects (via cAMP elevation in cardiac tissue) - **Diuresis:** Mild diuretic effect ### Clinical Pharmacokinetics - **Therapeutic range:** 10–20 μg/mL - **Narrow therapeutic index:** Toxicity risk above 20 μg/mL - **Metabolism:** Hepatic (CYP1A2, CYP3A4) - **Half-life:** 3–9 hours (variable, affected by age, smoking, liver disease) **Warning:** Theophylline has a narrow therapeutic window; toxicity (arrhythmias, seizures, nausea) occurs at only slightly higher concentrations. Plasma level monitoring is essential.